Larry Flake, MD
Family Medicine · Shreveport, LANPI 1386670917
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.1% of the total across 1,185 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,185 payments — averaging $16.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Biohaven Pharmaceutical Holding Company Ltd.$2K
- AstraZeneca$2K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Boehringer Ingelheim$1K
- plus $10K from 54 others
What the payments were for
- Consulting fees$1,2006%
- Travel & lodging$3042%
- Food & beverage$18,27191%
- Education$2131%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,048 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 108 | $140,993 |
| JardianceEmpagliflozin | 96 | $107,105 |
| MounjaroTirzepatide | 57 | $59,162 |
| FarxigaDapagliflozin Propanediol | 45 | $52,356 |
| EliquisApixaban | 58 | $47,665 |
| JanuviaSitagliptin Phosphate | 52 | $38,338 |
| RybelsusSemaglutide | 37 | $33,370 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 32 | $29,870 |
| Xigduo XrDapaglifloz Propaned/Metformin | 26 | $26,837 |
| VraylarCariprazine Hcl | 12 | $20,222 |
| NuedextaDextromethorphan Hbr/Quinidine | 13 | $19,303 |
| LinzessLinaclotide | 24 | $17,458 |
| Dexlansoprazole DrDexlansoprazole | 24 | $11,552 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $9,959 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $9,882 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,383 | $174,362145 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $1,024 | $139,851139 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $1,653 | $70,65775 claims |
| Lilly USA, LLCMounjaro | $1,234 | $59,16257 claims |
| PfizerEliquis | $979 | $47,66558 claims |
| MerckJanuvia, Janumet Xr | $590 | $46,65268 claims |
| AbbVieVraylar, Linzess, Synthroid | $3,185 | $41,96982 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $215 | $19,30313 claims |
| GSKTrelegy Ellipta | $853 | $9,88213 claims |
| Daiichi Sankyo Inc.Welchol | $269 | $9,78512 claims |
| Johnson & JohnsonInvokana | $401 | $6,32611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Shreveport
- Michael FlemingShreveport$165K
- Krishna SinghShreveport$22K
- Russell CarrShreveport$17K
- Richard KammShreveport$17K
- Wendy MosesShreveport$16K
- William GibsonShreveport$13K
- Christine SmithBaton Rouge$185K
- Thomas DansbyMonroe$169K
- Robert St AmantGonzales$156K
- William HathawaySpringhill$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.